byfavo-en
Stelopharm GmbH
Ihr zuverlässiger Partner
für die Distribution von
pharmazeutischen Produkten
Stelopharm GmbH
your reliable partner for the distribution
of pharmaceutical products
The following content is intended for
medical professionals only.
BYFAVO®
Byfavo 20 mg powder for solution for injection
Byfavo 50 mg powder for concentrate for solution for injection/infusion
Manufactured in Europe
INDICATIONS1
BYFAVO 20 mg:
- Each vial contains remimazolam besylate equivalent to 20 mg remimazolam.
- After reconstitution each mL contains 2.5 mg remimazolam.
- Excipient with known effect: Each vial contains 79.13 mg of dextran 40 for injection.
BYFAVO 50 mg:
- Each vial contains remimazolam besylate equivalent to 50 mg remimazolam.
- After reconstitution each mL of concentrate contains 5 mg remimazolam.
- Dilution is required to reach final concentration of 1-2 mg/mL.
- Excipient with known effect: Each vial contains 198 mg of dextran 40 for injection.
For the full list of excipients, see Product Catalog 07/2024 section 6.1
Method of administration:
Byfavo 20 mg: Remimazolam is indicated in adults for procedural sedation.
Byfavo 50 mg: Remimazolam 50 mg is indicated in adults for intravenous induction and maintenance of general anaesthesia.
1Byfavo® Summary of Product Characteristics, as of 07/2024
You can find the product information on the website of the European Medicines Agency here.